SCHEMBL23918324

SCHEMBL23918324

CC(C)(C)OC(=O)Nc1cccc(CCC(=O)Nc2cncc(Br)c2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.45
GAA P10253 2/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2C19 P33261 1/20 0.45
HDAC4 P56524 1/20 0.44
SIRT2 Q8IXJ6 2/20 0.44
SIRT1 Q96EB6 1/20 0.44
SIRT3 Q9NTG7 1/20 0.44
RAB9A P51151 1/20 0.44
ALDH1A1 P00352 3/20 0.43
HPGD P15428 1/20 0.43
HDAC3 O15379 2/20 0.43
HDAC1 Q13547 2/20 0.43
HDAC2 Q92769 2/20 0.43
HDAC10 Q969S8 2/20 0.43
HDAC8 Q9BY41 2/20 0.43
RORC P51449 1/20 0.43
MEN1 O00255 1/20 0.42
LMNA P02545 1/20 0.42
ALOX12 P18054 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30422559 1.00 MAPT (0.45) MAPTGAACYP3A4CYP2C19HDAC4
SCHEMBL22575272 0.84 MAPT (0.56) MAPTGAAHDAC4SIRT2SIRT1
SCHEMBL10195848 0.84 MAPT (0.62) MAPTGAACYP3A4CYP2C19SIRT2
SCHEMBL1502539 0.81 NAMPT (0.48) MAPTGAACYP3A4CYP2C19HDAC4
SCHEMBL30195889 0.80 NAMPT (0.57) GAARAB9AALDH1A1HDAC3HDAC1
SCHEMBL23918285 0.80 NAMPT (0.57) GAARAB9AALDH1A1HDAC3HDAC1
SCHEMBL13623204 0.78 MAPT (0.54) MAPTGAACYP3A4CYP2C19HDAC4
SCHEMBL4167491 0.78 CA1 (0.46) CYP3A4CYP2C19HDAC4RAB9AHDAC3
SCHEMBL307257 0.78 RAB9A (0.58) MAPTGAARAB9AALDH1A1HPGD
SCHEMBL8214435 0.78 CYP3A4 (0.48) MAPTGAACYP3A4CYP2C19SIRT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11667651-B2 Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors HIBERCELL, INC. (US) 2023-06-06 US disclosed
US-11667651-B2 Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors HIBERCELL, INC. (US) 2023-06-06 US disclosed
US-20210317136-A1 AMINOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS HIBERCELL, INC. 2021-10-14 US disclosed
CN-112020500-A Aminopyridine derivatives as inhibitors of phosphatidylinositol phosphokinase 拉文纳制药公司 2020-12-01 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11667651-B2 Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors PIP5K1B, PIP5K1A, PIP5K1C MAPT 1208/4885GAA 2250/4885CYP3A4 1436/4885
US-20210317136-A1 AMINOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS PIP5K1B, PIP5K1A, PIP5K1C MAPT 1208/4885GAA 2250/4885CYP3A4 1436/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.